Optimization of antiviral therapy in CHB - an experience of real practice
분야
의약학 > 내과학
저자
( Deepak Amarapurkar )
발행기관
대한간학회
간행물정보
KASL 2012년, 제2012권 151~156쪽(총6쪽)
파일형식
27405448.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    4,000원
    적립금
    120원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    Despite implementation of universal Hepatitis B Virus (HBV) vaccination programme, HBV related chronic liver disease and Hepatocellular carcinoma (HCC) are major cause of morbidity and mortality in Asian Pacific region(APR). Currently eight drugs are approved for the treatment of chronic hepatitis B infection. These are 1) Interferon alpha 2a/2b 2) Lamivudine 3) Adefovir 4) Entecavir 5) Talbuviduine 6)Tenofovir 7) Peginterferon alpha 2a/ 2b 8) Thymocin alpha. Emcetrabine and Tenofovir are available for treatment of HBV and HIV co-infections. While selecting primary treatment agent a careful balance between long term benefits and long term risk should be evaluated. Long term benefits are in the form of antiviral potency and durability of response, while long term risks are side effects and drug resistance. While selecting the treatment important issues are 1) ease of administration 2) duration of treatment 3) costs of treatment and monitoring 4) Patient and provider preference & 5) contraindication. In real life scenario accessibility to treatment remains a significant challenge for many chronically infected adults in the APR. High cost and lack of reimbursement are the driving factors limiting effective diagnosis and treatment of chronic hepatitis B in the APR.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.